Ideaya Biosciences, Inc. · NASDAQ:IDYA
Ideaya Biosciences — Investor Presentation (March 2026)
27 slides from Ideaya Biosciences's investor presentation, Mar 9, 2026
Slide 1: Improving Lives Through Transformative Precision Medicines
March 2026 Improving Lives Through Transformative Precision Medicines Corporate Presentation NASDAQ: IDYA
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the “Company”) and involve known and unknown risks, uncertainti
Slide 3: IDEAYA's Vision is to Build a Leading Precision Medicine Oncology Company
IDEAYA’s Vision is to Build a Leading Precision Medicine Oncology Company IDEAYA Research and Development Strategy Clinical Pipeline Focus Areas First-in-Class & Darovasertib Best-in-Class Predictive Biomarkers Prolong survival, preserve the Programs eye and vision in uveal melanoma ADC+DDR Combos A
Slide 4: IDEAYA's Proven Drug Discovery Engine in Precision Medicine Oncology
IDEAYA’s Proven Drug Discovery Engine in Precision Medicine Oncology Integrated Platform to Deliver Renewable Pipeline of Potential First-in-Class Programs Core IDEAYA Drug Discovery Capabilities 6 internally discovered Candidates delivered clinical stage molecules against difficult-to-drug CRISPR-b
Slide 5: Deep Pipeline Enables Combinations and Targeting of Multiple Solid Tumor Indications
Deep Pipeline Enables Combinations and Targeting of Multiple Solid Tumor Indications Phase 3 / Collaboration Target Indication(s) Phase 1 Phase 2 Potential Registrational partners 1L metastatic UM, HLA*A2(-) + crizotinib1 combination Darovasertib/ Neoadjuvant primary UM Uveal Melanoma PKC 1L metasta
Slide 6: Uveal Melanoma is a Rare, Aggressive Form of Cancer with Poor Prognosis
Darovasertib Uveal Melanoma (UM) is a Rare, Aggressive Form of Cancer with Poor Prognosis Patients face severe consequences with limited treatment options at all stages of disease Primary UM Metastatic UM (Localized disease in the eye) (Systemic disease) > 3,000 diagnosed in the U.S. per year ~50% p
Slide 7: Darovasertib Has a Unique Mechanism of Action Targeting the Primary Driver of Disease
Darovasertib Has a Unique Mechanism of Action Targeting the Primary Driver of Disease Activating mutations in GNAQ/11 drive PKC overactivation in nearly all UM patients Primary UM Metastatic UM • Oral, selective inhibitor of PKC, the key Pathway activations by mutations in GNAQ/11 Pathway activation
Slide 8: Darovasertib Has Potential To Be the First Targeted Therapy for All Stages of UM
Darovasertib Has Potential To Be the First Targeted Therapy for All Stages of UM Robust clinical development plan across the uveal melanoma patient journey Diagnosis Primary local therapy Metastasis Progression Primary Uveal Melanoma Metastatic Uveal Melanoma Neoadjuvant Adjuvant HLA*A2-negative HLA
Slide 9: Darovasertib + Crizotinib Continue to Drive Robust Responses
Darovasertib + Crizotinib Continue to Drive Robust Responses Single-arm trial demonstrated favorable ORR versus historical trials and meta-analysis in mUM 60% Best Overall Response Progressive Disease Best % Changes from Baseline Response 40% Well-tolerated, with a mean duration Stable Disease
Slide 10: First Reported Overall Survival with Darovasertib + Crizotinib
First Reported Overall Survival with Darovasertib + Crizotinib Median PFS and OS compared favorably to historical meta-analyses in front-line mUM Median PFS Median OS + Censored + Censored Median PFS (95% CI) Median OS (95% CI) 7.0 Months (3.8, 7.7) 21.1 Months (12.5, 27.1) Survival Probability Surv
Slide 11: Pivotal Phase 2/3 Trial in HLA*A2-Negative mUM
Pivotal Phase 2/3 Trial in HLA*A2-Negative mUM Pursuing approval of the first systemic therapy for an underserved metastatic population Trial Design Clinical Endpoints Multi-arm, Patients receive darovasertib + crizotinib Primary: Multi-stage, • PFS per RECIST 1.1 (BICR) for potential Open-label 300
Slide 12: Primary Phase Efficacy Results in Neoadjuvant UM
Primary Phase 2 Efficacy Results in Neoadjuvant UM Robust tumor shrinkage leading to eye preservation and visual improvements Cohort 1 (Enucleation) Cohort 2 (Plaque Brachytherapy) Tumor Shrinkage and Eye Preservation Tumor Shrinkage and Visual Improvement 50% 50% 40% Product of Apical Height and La
Slide 13: Pivotal Phase 3 Trial in Neoadjuvant UM
Pivotal Phase 3 Trial in Neoadjuvant UM Evaluating the ability of darovasertib to preserve eyes and protect long-term vision Trial Design Clinical Endpoints Primary: Neoadjuvant darovasertib Primary Local Therapy • Enucleation Cohort: 300mg BID up to 6 months (if needed) Eye preservation rate >10% w
Slide 14: Building a Franchise of TOP1 ADCs to Synergize with IDE161 (PARG inhibitor)
DLL3 ADC Building a Franchise of TOP1 ADCs to Synergize with IDE161 (PARG inhibitor) Lead ADC product candidate, IDE849, has TOP1 payload and high DLL3 affinity and selectivity Tumor-selective delivery of TOP1 ADC in combination with IDE849 systemic PARG inhibition via IDE161 may synergize to increa
Slide 15: IDE161 Has Potential to Improve Efficacy and Durability of TOP1 ADCs
IDE161 Has Potential to Improve Efficacy and Durability of TOP1 ADCs Combination mechanism has shown broad potential across multiple solid tumor models TOP1 inhibitor-induced DNA lesion PARG inhibition by IDE161 maximizes TOP1cc TOP1 ADC payload efficacy Deparylation repair by PARG Cell proliferatio
Slide 16: DLL3 Expression is Upregulated in a Broad Range of Solid Tumor Types
DLL3 Expression is Upregulated in a Broad Range of Solid Tumor Types ~164,000 potential addressable patients in the U.S. alone Estimated DLL3-Positive U.S. Annual Incidence by Tumor Type 16% 7% ~7K Estimated DLL3+ 72-78% ~6K Frequency by NEC Subtype 11% ~19K Pulmonary 63% ~21K Large-Cell NEC 34% 43%
Slide 17: IDE849 (SHR-4849) Demonstrated Compelling Initial Efficacy in SCLC
IDE849 (SHR-4849) Demonstrated Compelling Initial Efficacy in SCLC Robust responses observed across multiple expansion doses tested in Phase 1 study * Progressive Disease 2.4 mg/kg 3.0 mg/kg 3.5 mg/kg 4.2 mg/kg Total (≥2.4 mg/kg) 2L Setting All 2L Setting All 2L Setting All 2L Setting All 2L Setting
Slide 18: Phase 1 PFS Data in SCLC Patients Treated with IDE849 (SHR-4849)
Phase 1 PFS Data in SCLC Patients Treated with IDE849 (SHR-4849) Encouraging preliminary evidence of durability across all lines of treatment Total (≥2.4 mg/kg) 2L Setting All (n=42) (n=86) 8 22 Events, n (%) (19.0%) (25.6%) NR 6.7 Median months 3-month rate (%) 93.3% 83.3% 6-month rate (%) 59.0% 55
Slide 19: IDE849 (SHR-4849) Clinical Development Overview
IDE849 (SHR-4849) Clinical Development Overview Potential monotherapy and combination opportunities in multiple DLL3-overexpressing tumors Preliminary Strategy Target Clinical Development Plan • Pursue potential mono- IDE849 therapy AA path in 2L+ Dose Escalation Expansion Cohort: SCLC SCLC and/or 2
Slide 20: IDE034 is a Potential First-in-Class B7H3/PTK7 TOP1 Bispecific ADC
B7H3/PTK7 ADC IDE034 is a Potential First-in-Class Phase 1 B7H3/PTK7 TOP1 Bispecific ADC Dual tumor-antigen binding to maximize tumor-specific PARG combination benefit in multiple solid tumors • Enhanced binding and • Substantial B7H3/PTK7 patient αB7H3 αPTK7 B7H3/PTK7 population across tumor types
Slide 21: IDE397 is the Backbone of Combination Strategies for MTAP-Deleted Solid Tumors
MTAP IDE397 is the Backbone of 3 Combination Strategies for MTAP-Deleted Solid Tumors MAT2A is central to support protein methylation and DNA repair in MTAP-/- tumors Combination strategies designed to Chromosome 9 amplify metabolic liabilities and genomic MTAP deletion leads to purines MTA accumula
Slide 22: There Are No FDA-Approved Therapies for MTAP-Deleted Solid Tumors
There Are No FDA-Approved Therapies for MTAP-Deleted Solid Tumors IDEAYA’s clinical strategy is focused on lung, urothelial and pancreatic cancers Estimated U.S. Annual Incidence in Priority Tumor Types MTAP-Deletion Frequency by Tumor Type1 Urothelial Cancer 26% ~27K Squamous NSCLC 19% Adeno NSCLC
Slide 23: Phase 2 IDE397 Monotherapy in MTAP-Deleted Lung and Urothelial Cancers
Phase 1 IDE397 Monotherapy in MTAP-Deleted Lung and Urothelial Cancers Best response by RECIST 1.1 at 30mg Phase 2 expansion dose 120% 60% Urothelial Best Response by RECIST (% change from baseline) 40% Adeno NSCLC Squamous NSCLC 20% ^^ PR PR PR PR PR PR PR PR CR 0% # -20% -40% Efficacy by RECIST 1.
Slide 24: PRMT5 Inhibitor IDE892 Exhibits Robust Selectivity and Combination Potential
PRMT5 Phase 1 PRMT5 Inhibitor, IDE892, Exhibits Robust Selectivity and Combination Potential with Phase 2 MAT2A Inhibitor IDE397 in MTAP-/- Preclinical Models Only active in MTAP-/- cells (HCT116 isogenic pair) IDE397 combination delivers CRs and reverses relapse HCT116 WT HCT116 MTAP-/- NCI-H838 MT
Slide 25: Next Generation, Potential First-In-Class Therapies in Phase 1 for Solid Tumors
Next Gen Next Generation, Potential First-In-Class Therapies in Phase 1 for Solid Tumors IDE275: Werner Helicase (WRN) Inhibitor Targeting MSI-H Cancers IDE574: dual KAT6/7 Inhibitor for mBC, Lung, Prostate and CRC Unique IDE275-bound helicase conformation can overcome intrinsic Histone acetyltransf
Slide 26: IDEAYA Biosciences: Building a Leading Precision Medicine Oncology Company
IDEAYA Biosciences: Building a Leading Precision Medicine Oncology Company Advancing a pipeline of 9 clinical stage programs across multiple solid tumor indications Target 2026 Pipeline Milestones Highlights Q1 2026 Q2 2026 H2 2026 Darovasertib Metastatic UM commercial readiness Darovasertib/ 1L Met
Slide 27: Improving Lives Through Transformative Precision Medicines
March 2026 Improving Lives Through Transformative Precision Medicines Corporate Presentation NASDAQ: IDYA
IDEAYA Biosciences — Investor Presentation (March 2026) on 6ix